Given that effective BW management is crucial in patients with both T1DM and T2DM, GLP-1 RAs are anticipated to be of particular benefit in treating T1DM in patients with obesity, including those with SPIDDM, due to their favorable extra pancreatic effects [16]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.